Ringe, J D <br/><br/>
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Jun 2003 
 - 743-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1462-0324 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/keg205  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Back Pain--drug therapy<br/>Bone Density--drug effects<br/>Calcaneus--physiopathology<br/>Diphosphonates--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Femur Neck--physiopathology<br/>Glucocorticoids--adverse effects<br/>Humans<br/>Hydroxycholecalciferols--therapeutic use<br/>Ibandronic Acid<br/>Injections, Intravenous<br/>Lumbar Vertebrae--physiopathology<br/>Male<br/>Middle Aged<br/>Osteoporosis--chemically induced<br/>Prospective Studies<br/>Spinal Fractures--prevention & control